Published: 11 May 2016
Author(s): Helena Pité, Marisa Braga da Cruz, Mário Morais-Almeida
Issue: May 2016
Section: Letters to the Editor

Cardiovascular diseases are major public health problems. ß-blockers therapy is indicated for the majority of patients with heart failure and coronary artery disease (Class I, Level of Evidence: A). These drugs are also first-line therapy for atrial fibrillation. However, ß-blocker use continues to be less than optimal, principally in patients with concomitant chronic obstructive lung diseases, such as asthma and chronic obstructive pulmonary disease (COPD).


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.